sponsored
PatientsVille.com Logo

PatientsVille

Tolterodine Medical Research Studies

Up-to-date List of Tolterodine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Tolterodine Medical Research Studies

Rank Status Study
1 Not yet recruiting A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Condition: Overactive Bladder (OAB)
Interventions: Drug: Myrbetriq;   Drug: Detrol LA
Outcome Measures: Patient tolerability assessed by the Tolerability Scale of the Overactive Bladder-satisfaction (OAB-S) questionnaire;   Patient preference from a 5-point scale;   Scales of the OAB-S questionnaire;   Change from baseline in number of incontinence episodes per 24 hours;   Change from baseline in number of micturitions per 24 hours
2 Unknown  Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
Condition: Prostatitis
Interventions: Drug: Tolterodine;   Drug: tamsulosin;   Drug: placebo
Outcome Measures: National Institutes of Health Chronic Prostatitis Symptom Index;   Peak urinary flow rate;   International Index of Erectile Function
3 Recruiting Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)
Conditions: Overactive Bladder;   Benign Prostatic Hyperplasia
Intervention: Drug: doxazosin plus Tolterodine SR
Outcome Measures: Numeric change of urgency episodes per 24 hours;   Changes in voiding diary parameters;   Change in symptom questionnaires;   Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue;   Change of uroflowmetry and PVR;   Incidence of acute urinary retention
4 Recruiting Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
Condition: Overactive Bladder
Interventions: Drug: Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets;   Drug: Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
Outcome Measures: Change in mean number of nocturnal voids from baseline;   Change in mean time to first nocturnal void from baseline;   Change in mean nocturnal urine volume from baseline;   Responder status;   Change in mean number of nocturnal voids from baseline for each visit;   Change in the impact on sleep as measured by the sleep rating scales from baseline
5 Recruiting Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Condition: Ureteral Obstruction
Interventions: Drug: Tamsulosin;   Drug: Tolterodine ER
Outcome Measure: Ureteral stent symptom questionnaire score
6 Unknown  Pharmacological vs Surgical Treatment for Mixed Incontinence
Conditions: Mixed Urinary Incontinence;   Urinary Incontinence, Stress;   Urinary Incontinence, Urge
Interventions: Drug: Tolterodine;   Procedure: tension free vaginal tape
Outcome Measures: improvement in subjective and objective measures of urinary incontinence;   assessment of pre-treatment predictors of success or failure of treatment;   assessment of pre-treatment predictors of requirement for alternative treatment
7 Recruiting Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome
Condition: Overactive Bladder
Interventions: Drug: Detrusitol 4mg QD and Oxybutynin ER 5mg QD;   Drug: Detrusitol 4mg QD
Outcome Measures: Change from Baseline in the Perception of Bladder Condition (PPBC) at different time points;   Change from Baseline in the Overactive Bladder Symptom Score (OABSS) at different time points;   Change from Baseline in the urinary sensation scale (USS) at different time points;   Change from Baseline in the International Prostate Symptom Score (IPSS) at different time points;   Change from Baseline in the maximum flow rate (Qmax) at different time points;   Change from Baseline in the voided volume at different time points;   Change from Baseline in the postvoid residual volume (PVR) at different time points;   Change from Baseline in the total prostate volume (TPV) at different time points;   Change from Baseline in the transition zone index (TZI) at different time points
8 Recruiting Combined Behavioral and Drug Treatment of Overactive Bladder in Men
Conditions: Overactive Bladder;   Lower Urinary Tract Symptoms
Interventions: Behavioral: Behavioral training;   Drug: Tolterodine + tamsulosin
Outcome Measures: Change in frequency of urination;   Urgency;   Urinary incontinence;   Nocturia;   Patient satisfaction;   Patient perceptions of improvement;   Overactive Bladder Questionnaire (OAB-q);   International Prostate Symptom Score (IPSS)
9 Unknown  Study of Herbmed Plus in Ureteral Stent Discomfort
Condition: Renal Calculi
Intervention: Drug: Herbmed plus
Outcome Measures: Comparative study for Safety , Efficacy of Herbmed plus and Tolterodine in management of ureteral stent discomfort.;   Tolerability of herbmed plus in management of ureteral stent discomfort
10 Recruiting Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)
Condition: Low Back Pain
Interventions: Drug: Oxycodone 15mg;   Drug: Clobazam;   Drug: Imipramine;   Drug: Tolterodine
Outcome Measures: Difference in NRS(pain scale) between measurement after and before drug administration;   Patients global impression of change scale after drug administration;   Pharmacogenetic variables(see before);   Pharmacokinetics: measure of Imipramine and desipramine blood levels;   Reliability of repeated quantitative sensory testing in the same patient
11 Recruiting Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients
Conditions: Urinary Incontinence;   Bladder Dysfunction
Intervention: Drug: Detrol LA
Outcome Measure: Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke. Develop pilot data of medical therapy (Detrol LA) in diabetic and stroke bladder dysfunction.
12 Recruiting Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Condition: Bladder Outlet Obstruction
Interventions: Drug: Detrusitol 4 mg QD;   Drug: Doxazosin 4 mg QD
Outcome Measures: The efficacy will be assessed using Patient Perception of Bladder Condition (PPBC) after the treatment day;   The efficacy will be assessed using International Prostate Symptom Score (IPSS) questionnaires after the treatment day;   The efficacy will be assessed using Overactive Bladder Symptom Score (OABSS) questionnaires after the treatment day;   To evaluate change of the total prostate volume (TPV) at different time points;   To evaluate change of Transition zone index (TZI) at different time points;   To evaluate change of Maximum flow rate (Qmax) at different time points;   To evaluate change of voided volume at different time points;   To evaluate change of postvoid residual volume (PVR) at different time points
13 Recruiting Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
Condition: Urinary Incontinence, Urge
Interventions: Drug: Anticholinergic medications;   Behavioral: Hypnotherapy
Outcome Measures: Urgency Urinary Incontinence episodes recorded on voiding diaries;   Evoked brain activation and resting connectivity on functional MRI;   Urinary urge incontinence cure;   Questionnaire scores;   urinary frequency and pad counts;   Irritable bowel syndrome and bowel symptoms and/or Painful Bladder/Interstitial Cystitis in this population
14 Recruiting Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.
Condition: Lower Urinary Tract Symptoms
Intervention: Drug: Tolterodine SR
Outcome Measures: Blood flow pattern after antimuscarinics;   Blood flow patterns between different LUTS subgroups
15 Unknown  Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome
Condition: Overactive Bladder
Intervention: Drug: DETRUSITOL
Outcome Measure: A significant correlation between reduced urinary symptoms and a reduction of more than 10 points in the OAB-8 score.
16 Recruiting OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER in Spinal Cord Injured Veterans With Neurogenic Detrusor Overactivity
Condition: Neurogenic Detrusor Overactivity
Interventions: Drug: onabotulinumtoxin A;   Drug: Oxybutynin ER
Outcome Measures: Primary endpoint;   The utility of urinary inflammatory markers as statistically significant predictors of treatment response.
17 Not yet recruiting Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers
Condition: Healthy
Interventions: Drug: Fesoterodine ER (fasted);   Drug: Fesoterodine SR3 (fasted);   Drug: Fesoterodine SR3 (fed);   Drug: Fesoterodine SR3 (sprinkle);   Drug: Fesoterodine SR4 (fasted);   Drug: Fesoterodine SR4 (fed);   Drug: Fesoterodine SR4 (sprinkle)
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2)
18 Unknown  An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
Condition: Bladder Outlet Obstruction
Intervention: Drug: Toviaz (Fesoterodine)
Outcome Measures: AUA symptom score;   Uroflowmetry and post-void residual

These studies may lead to new treatments and are adding insight into Tolterodine etiology and treatment.

A major focus of Tolterodine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Tolterodine